The Cancer Genome Atlas completes detailed ovarian cancer analysis

	Tweet

As part of The Cancer Genome Atlas (TCGA) projectIcon indicating that a link will open an external site., UNC Lineberger researchers have contributed to the most comprehensive and integrated view of cancer genes for any cancer type produced to date.

The UNC team, which includes Charles Perou, PhD, professor of pathology and laboratory medicine and genetics, Neil Hayes, MD, associate professor of hematology/oncology, and Katie Hoadley, PhD, Research Associate, completed the microRNA and mRNA microarray analysis that contributed to the findings.

Ovarian serous adenocarcinoma tumors from 500 patients were examined and the analyses are reported in the June 30, 2011 issue of the journal Nature.  Serous adenocarcinoma accounts for about 85 percent of all ovarian cancer deaths.

The researchers confirmed that mutations in the tumor suppressor gene TP53, are present in more than 96 percent of these cancers.  Tumor suppressor genes produce proteins that normally prevent cancer formation.  When the genes mutate and those protein functions are disrupted, tumors can form.

The team also found sets of genes associated with different patient survival patterns, indentifying a set of 108 genes associated with poor survival and 85 genes associated with better survival.  Overall, the five-year survival rate for ovarian cancer is 31 percent, meaning that there is an urgent need for a better understanding of and therapeutic targets for the disease.

“These are exactly the types of cancers for which The Cancer Genome Atlas project can make a difference, providing the resources and collaborative scientific power to establish new investigative avenues aimed at treatments targeted to the specific biology of ovarian cancer,” said Hayes.

Investigators on the project also searched for existing drugs that might inhibit genes that seem to play a role in ovarian cancer.  They identified 68 genes that could be targeted by existing FDA-approved or experimental therapeutic compounds.  For example, PARP inhibitors, which have been tested in clinical trials at UNC and elsewhere, may be able to counteract a DNA repair gene observed in half of the ovarian tumors studied.

TCGA is jointly funded and managed by the National Cancer Institute indicating that a link will open an external site.(NCI) and the http://www. genome.gov/ indicating that a link will open an external site. National Human Genome Research Institute (NHGRI), both part of the National Institutes of Health.  As participants in TCGA, UNC Lineberger scientists have also been involved in findings related to subtypes of the brain tumor glioblastoma and of lung cancers.

###

UNC Lineberger Comprehensive Cancer Center
Campus Box 7295, Chapel Hill, NC 27599
Appointments: 1-866-869-1856

RELATED STORIES:
New drug comb may lengthen ovarian cancer survival   Low dose naltrexone (LDN): Harnessing the body’s own chemistry to treat human ovarian cancer   Cancer stem cells recruit normal stem cells to fuel ovarian cancer, U-M study finds   Women with Certain Type of Ovarian Cancer and BRCA Gene Mutation Have Improved Survival at 5 Years   Motor protein may offer promise in ovarian cancer treatment   GPs take more than a month to record ovarian cancer diagnosis in one in 10 cases   Low-fat diet possibly linked to lower risk of ovarian cancer   Goodness of milk ‘offset by ovarian cancer risk’   FDA clears biomarker test for ovarian cancer   Women often opt to surgically remove their breasts, ovaries to reduce cancer risk   Genetic factors implicated in survival gap for breast, ovarian or prostate cancer   Birth after cancer treatment with removal and storage of ovary   Ovarian cancer patients survive longer with BRCA2 mutated in tumors   New Treatment Implications for Ovarian Cancer Unveiled   New Antibody Offers Hope for Treating Ovarian, Breast Cancer   Novel Study Using Reoviruses Against Ovarian Cancer Pushes Forward   PET-CT Highly Accurate for Detecting Ovarian Cancer Recurrence   BRCA2 genetic mutation associated with improved survival and chemotherapy response in ovarian cancer   Soy may lessen risk of endometrial, ovarian cancers   Ovary removal could be risky for young women   Hormone therapy linked to ovarian cancer risk   Clues to Ovarian Cancer’s Deadly Secrets

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]